Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $68.8 million.

  • Lineage Cell Therapeutics' Total Liabilities rose 11648.74% to $68.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.8 million, marking a year-over-year increase of 11648.74%. This contributed to the annual value of $36.2 million for FY2024, which is 715.46% down from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Total Liabilities of $68.8 million as of Q3 2025, which was up 11648.74% from $43.7 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Total Liabilities peaked at $83.6 million during Q4 2021, and registered a low of $11.2 million during Q2 2021.
  • For the 5-year period, Lineage Cell Therapeutics' Total Liabilities averaged around $41.5 million, with its median value being $39.5 million (2023).
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Total Liabilities soared by 55237.09% in 2021, and later tumbled by 3815.92% in 2022.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Total Liabilities stood at $83.6 million in 2021, then crashed by 38.16% to $51.7 million in 2022, then fell by 24.61% to $39.0 million in 2023, then decreased by 7.15% to $36.2 million in 2024, then surged by 90.14% to $68.8 million in 2025.
  • Its last three reported values are $68.8 million in Q3 2025, $43.7 million for Q2 2025, and $34.1 million during Q1 2025.